Prognostic value of preoperative plasma fibrinogen levels in resected stage I non‐small cell lung cancer

Abstract

Background: The number of surgical procedures has increased among patients with early-stage lung cancer. If the poor prognostic factors for stage I non-small cell lung cancer (NSCLC) can be simply validated preoperatively, appropriate treatment will be provided. The current study aimed to evaluate the prognostic value of preoperative plasma fibrinogen levels in patients with resected stage I NSCLC. Methods: We retrospectively analyzed the clinicopathological information of patients (n = 149) who underwent lobectomy for stage I NSCLC between May 2014 and July 2016. Data about peripheral blood analysis, histopathological finding, and follow-up assessment results were collected from the databases. Patients were divided into the low and high fibrinogen groups. Univariate and multivariate analyses were performed to evaluate the predictors of recurrence and survival. Results: Compared with the low fibrinogen group (<377 mg/dl), the high fibrinogen group (≥377 mg/dl) had a significantly greater number of male participants (p = 0.04), smokers (p < 0.001), and those with elevated cytokeratin antigen levels (p = 0.04), lymphatic invasion (p = 0.007), and squamous cell carcinoma (p < 0.001). Plasma fibrinogen level was considered a significant independent factor for recurrence and overall survival on both the univariate and multivariate analyses (p < 0.001 and p = 0.010) and the multivariate analysis alone (p = 0.020 and p < 0.012). Conclusion: Preoperative plasma fibrinogen level might be a useful predictor of recurrence and survival in patients with stage I NSCLC. The treatment strategy for patients with high fibrinogen levels could be cautiously considered preoperatively.

Nomograms Based on Fibrinogen, Albumin, Neutrophil-Lymphocyte Ratio, and Carbohydrate Antigen 125 for Predicting Endometrial Cancer Prognosis

“…Previous studies have shown that coagulation-related factors such as fibrinogen, D-dimer, and platelets are closely related to the prognosis of patients with malignant tumors [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ]. The relationship between fibrinogen and malignant tumors has been widely studied.…”

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities

“…Levels of fibrinogen increase in inflammatory states as part of the acute-phase response. In patients who underwent surgical resection of stage I NSCLC, those with pre-operative fibrinogen ≥ 377 mg/dl had poorer relapse-free survival (RFS) and OS [38]. D-dimer, prothrombin (PT), activated partial thromboplastin time (APPT), thrombin time (TT), and the international normalised ratio (INR) have also been identified as independent prognostic factors in lung cancer [39,40].…”

Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

“…2023; 22(2): 56-64 фоцитов (neutrophil-to-lymphocyte ratio -NLR)простой и доступный показатель, отражающий дисбаланс между различными звеньями иммунитета [12]; уровень С-реактивного белка и альбумина (Glasgow Prognostic Score) [13]; сочетание NLR, уровня лактатдегидрогеназы (ЛДГ) и уровня экспрессии PD-L1-lung immuno-oncology prognostic score (LIPS-3) [14]; оценка NLR, ЛДГ и уровня альбумина в плазме крови (Gustave Roussy Immune (GRIm)-Score) [15] и, собственно, Lung Immune Prognostic Index (LIPI) -определение NLR и уровня ЛДГ до начала иммунотерапии [16][17][18][19][20][21][22]. Кроме того, возможно включение в прогностическую модель и других клинических доступных факторов, коррелирующих с неблагоприятным прогнозом и достаточно часто выявляемых у пациентов с метастатическим НМРЛ: анемия [23,24], тромбоцитоз [25] и высокий уровень фибриногена [26]. Подобные шкалы с успехом применяются в других нозологиях, например при раке почки.…”